The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes

Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identify CYPs metabolizing ellipticine. In this review we focus on comparison between the in vitro and in vivo studies and show a necessity of both approaches to obtain valid information on CYP enzymes contributing to ellipticine metabolism. Discrepancies were found between the CYP enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the detoxification products. The finding showing that cytochrome b5 alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4 explained this paradox. Whereas the detoxification of ellipticine by CYP1A and 3A is either decreased or not changed by cytochrome b5, activation leading to ellipticine-DNA adducts increased considerably. We show that (I) the pharmacological effects of ellipticine mediated by covalent ellipticine-derived DNA adducts are dictated by expression levels of CYP1A, 3A and cytochrome b5, and its own potency to induce these enzymes in tumor tissues, (II) animal models, where levels of CYPs are either knocked out or induced are appropriate to identify CYPs metabolizing ellipticine in vivo, and (III) extrapolation from in vitro data to the situation in vivo is not always possible, confirming the need for these animal models.

[1]  R. Gniadecki,et al.  Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage , 2015, Leukemia & lymphoma.

[2]  Charlotte M. Miller,et al.  Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells , 2014, Investigational New Drugs.

[3]  V. Arlt,et al.  Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions. , 2014, Toxicology.

[4]  E. Frei,et al.  Ellipticines as DNA-targeted chemotherapeutics. , 2014, Current medicinal chemistry.

[5]  V. Adam,et al.  Expression Levels of Enzymes Metabolizing an Anticancer Drug Ellipticine Determined by Electromigration Assays Influence its Cytotoxicity to Cancer Cells - A Comparative Study , 2014, International Journal of Electrochemical Science.

[6]  V. Arlt,et al.  The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice. , 2013, Neuro endocrinology letters.

[7]  D. Dasgupta,et al.  Ellipticine binds to a human telomere sequence: an additional mode of action as a putative anticancer agent? , 2013, Biochemistry.

[8]  C. Wolf,et al.  Evidence That Cytochrome b5 and Cytochrome b5 Reductase Can Act as Sole Electron Donors to the Hepatic Cytochrome P450 System , 2013, Molecular Pharmacology.

[9]  W. J. Andrews,et al.  Old Drug, New Target , 2013, The Journal of Biological Chemistry.

[10]  R. Kizek,et al.  The Anticancer Drug Ellipticine Induces Cytochromes P450 1A1, 1A2 and 3A, Cytochrome b5 and NADPH:Cytochrome P450 Oxidoreductase in Rat Liver, Kidney and Lung , 2013 .

[11]  R. Kizek,et al.  Electrochemical Determination of Enzymes Metabolizing Ellipticine in Thyroid Cancer Cells - a Tool to Explain the Mechanism of Ellipticine Toxicity to these Cells , 2013, International Journal of Electrochemical Science.

[12]  C. Wolf,et al.  Evidence That Cytochrome b 5 and Cytochrome b 5 Reductase Can Act as Sole Electron Donors to the Hepatic Cytochrome P 450 System s , 2013 .

[13]  Z. Dvořák,et al.  Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. , 2012, Toxicology.

[14]  Charlotte M. Miller,et al.  Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles , 2012 .

[15]  V. Arlt,et al.  Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling. , 2012, Toxicology letters.

[16]  V. Adam,et al.  The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. , 2012, Current medicinal chemistry.

[17]  F. Guengerich,et al.  Contributions of human enzymes in carcinogen metabolism. , 2012, Chemical research in toxicology.

[18]  R. Kizek,et al.  Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases. , 2012, Chemical research in toxicology.

[19]  V. Adam,et al.  Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. , 2012, Pharmacology & therapeutics.

[20]  Jieun Park,et al.  Ellipticine induces apoptosis in human endometrial cancer cells: the potential involvement of reactive oxygen species and mitogen-activated protein kinases. , 2011, Toxicology.

[21]  J. Hudeček,et al.  Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy. , 2011, Biochemical pharmacology.

[22]  V. Arlt,et al.  Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  R. Kizek,et al.  Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. , 2011, Neuro endocrinology letters.

[24]  E. Frei,et al.  Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. , 2011, Biochimica et biophysica acta.

[25]  Yunfeng Zhao,et al.  Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells , 2011, Apoptosis.

[26]  Václav Martínek,et al.  Glycosylation protects proteins against free radicals generated from toxic xenobiotics. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  K. Takeda,et al.  α5β1 integrin antagonists reduce chemotherapy‐induced premature senescence and facilitate apoptosis in human glioblastoma cells , 2010, International journal of cancer.

[28]  Barbora Mrázová,et al.  Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney. , 2010, Neuro endocrinology letters.

[29]  O. Hankinson,et al.  Functional Characterization of Human Cytochrome P450 2S1 Using a Synthetic Gene-Expressed Protein in Escherichia coli , 2009, Molecular Pharmacology.

[30]  O. Hankinson,et al.  Fatty Acid Hydroperoxides Support Cytochrome P450 2S1-Mediated Bioactivation of Benzo[a]pyrene-7,8-dihydrodiol , 2009, Molecular Pharmacology.

[31]  Václav Martínek,et al.  Preparation of a biologically active apo-cytochrome b5 via heterologous expression in Escherichia coli. , 2009, Protein expression and purification.

[32]  R. Kizek,et al.  The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. , 2009, Biochemical pharmacology.

[33]  D. Waxman,et al.  Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer , 2009, Cancer Gene Therapy.

[34]  K. Fang,et al.  Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells. , 2009, Lung cancer.

[35]  E. Frei,et al.  Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. , 2009, Neuro endocrinology letters.

[36]  R. Finn,et al.  Defining the in Vivo Role for Cytochrome b5 in Cytochrome P450 Function through the Conditional Hepatic Deletion of Microsomal Cytochrome b5*S⃞ , 2008, Journal of Biological Chemistry.

[37]  J. Hudeček,et al.  Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. , 2008, Neuro endocrinology letters.

[38]  X. Qi,et al.  Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. , 2008, Kidney international.

[39]  V. Arlt,et al.  Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. , 2008, Toxicology and applied pharmacology.

[40]  V. Arlt,et al.  Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo : experiments with Hepatic Cytochrome P450 Reductase Null mice , 2008 .

[41]  J. Dennis,et al.  A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization , 2008, Apoptosis.

[42]  D. Waxman,et al.  Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment , 2007, Molecular Cancer Therapeutics.

[43]  L. Waskell,et al.  Cytochrome b5 Increases the Rate of Product Formation by Cytochrome P450 2B4 and Competes with Cytochrome P450 Reductase for a Binding Site on Cytochrome P450 2B4* , 2007, Journal of Biological Chemistry.

[44]  R. Vaclavikova,et al.  The Anticancer Drug Ellipticine Is a Potent Inducer of Rat Cytochromes P450 1A1 and 1A2, Thereby Modulating Its Own Metabolism , 2007, Drug Metabolism and Disposition.

[45]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. , 2007, Cancer letters.

[46]  E. Frei,et al.  Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. , 2007, Toxicology.

[47]  E. Frei,et al.  Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12‐hydroxyellipticine and 13‐hydroxyellipticine , 2007, International journal of cancer.

[48]  E. Frei,et al.  Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. , 2006, Neuro endocrinology letters.

[49]  J. Hudeček,et al.  Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. , 2006, General physiology and biophysics.

[50]  Eva Frei,et al.  Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. , 2006, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[51]  Chun-ching Lin,et al.  Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. , 2006, Life sciences.

[52]  V. Arlt,et al.  Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. , 2006, Cancer letters.

[53]  J. Hudeček,et al.  The Effect of pH on Peroxidase-Mediated Oxidation of and DNA Adduct Formation by Ellipticine , 2006 .

[54]  L. Waskell,et al.  Role of cytochrome b5 in catalysis by cytochrome P450 2B4. , 2005, Biochemical and biophysical research communications.

[55]  Graeme I Murray,et al.  Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers , 2005, Clinical Cancer Research.

[56]  Oliver Hankinson,et al.  CYP2S1: a short review. , 2005, Toxicology and applied pharmacology.

[57]  Chun-ching Lin,et al.  The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. , 2005, Cancer letters.

[58]  C. Wolf,et al.  Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. , 2005, Cancer research.

[59]  Chun-ching Lin,et al.  The anti-proliferative inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction , 2005, Anti-cancer drugs.

[60]  B. Sopko,et al.  Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. , 2005, Cancer research.

[61]  Marie Stiborová,et al.  Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:Cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid‐DNA adducts found in patients with urothelial cancer , 2005, International journal of cancer.

[62]  J. Hudeček,et al.  The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide , 2004, Cancer Research.

[63]  M. Poirier Chemical-induced DNA damage and human cancer risk , 2004, Nature Reviews Cancer.

[64]  N. Garbett,et al.  Extending nature's leads: the anticancer agent ellipticine. , 2004, Current medicinal chemistry. Anti-cancer agents.

[65]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling , 2003, International journal of cancer.

[66]  Jiandong Chen,et al.  Rescue of mutant p53 transcription function by ellipticine , 2003, Oncogene.

[67]  David Bouwman,et al.  Cytochrome p450 and glutathione transferase expression in human breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  C. Wolf,et al.  Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase* , 2003, The Journal of Biological Chemistry.

[69]  J. Schenkman,et al.  The many roles of cytochrome b5. , 2003, Pharmacology & therapeutics.

[70]  E. Frei,et al.  Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. , 2003, Chemical research in toxicology.

[71]  E. Frei,et al.  The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. , 2001, Biochemical pharmacology.

[72]  H. Yamazaki,et al.  Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. , 2001, The Journal of biological chemistry.

[73]  R. Godschalk,et al.  Exposure-route-dependent DNA adduct formation by polycyclic aromatic hydrocarbons. , 2000, Carcinogenesis.

[74]  S. McKeown,et al.  Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. , 1999, Anti-cancer drug design.

[75]  E. Sugikawa,et al.  Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. , 1999, Anticancer research.

[76]  M. Sefkow,et al.  Epothilone A-D and their thiazole-modified analogs as novel anticancer agents , 1999 .

[77]  P. Wormell,et al.  Spectroscopic studies of 9-hydroxyellipticine binding to DNA. , 1998, Biopolymers.

[78]  J N Weinstein,et al.  Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. , 1998, Molecular pharmacology.

[79]  H. Yamazaki,et al.  Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. , 1997, Archives of biochemistry and biophysics.

[80]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[81]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[82]  E. Sugikawa,et al.  Inhibition of p53 Protein Phosphorylation by 9‐Hydroxyellipticine: A Possible Anticancer Mechanism , 1995, Japanese journal of cancer research : Gann.

[83]  G. Murray,et al.  Cytochrome P450 expression in tumours. , 1995, The Journal of pathology.

[84]  N. Osheroff,et al.  Topoisomerase II Binds to Ellipticine in the Absence or Presence of DNA. , 1995, The Journal of Biological Chemistry.

[85]  F. Beland,et al.  DNA adduct formation and T-lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene. , 1995, Cancer Research.

[86]  S. Nesnow,et al.  Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. , 1995, Cancer research.

[87]  M. Singh,et al.  High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. , 1994, Biochemistry.

[88]  M. Waterman Heterologous expression of cytochrome P-450 in Escherichia coli. , 1993, Biochemical Society transactions.

[89]  M. Fritsche,et al.  Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. , 1993, Oncogene.

[90]  C. Paoletti,et al.  Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. , 1992, Molecular pharmacology.

[91]  M. Hsu,et al.  Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. , 1992, Nucleic acids research.

[92]  T. Eling,et al.  Xenobiotic metabolism by prostaglandin H synthase. , 1992, Pharmacology & therapeutics.

[93]  C. Paoletti,et al.  Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. , 1991, Nucleic acids research.

[94]  J. Bergman,et al.  1H-NMR studies of the interaction between a self-complementary deoxyoligonucleotide duplex and indolo[2,3-b]quinoxaline derivatives active against herpes virus. , 1991, European journal of biochemistry.

[95]  J. Belehradek,et al.  DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. , 1991, The Journal of biological chemistry.

[96]  T. Eling,et al.  Prostaglandin H synthase and xenobiotic oxidation. , 1990, Annual review of pharmacology and toxicology.

[97]  C. Auclair Multimodal action of antitumor agents on DNA: the ellipticine series. , 1987, Archives of biochemistry and biophysics.

[98]  K Randerath,et al.  32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice. , 1984, Carcinogenesis.

[99]  D. Phillips,et al.  32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice. , 1984, Carcinogenesis.

[100]  D. Silveira,et al.  Comparative physiological disposition of ellipticine in several animal species after intravenous administration. , 1978, Drug metabolism and disposition: the biological fate of chemicals.

[101]  V. Reinhold,et al.  Characterization of the metabolites of ellipticine in rat bile. , 1978, Drug metabolism and disposition: the biological fate of chemicals.

[102]  K W Kohn,et al.  Intercalative binding of ellipticine to DNA. , 1975, Cancer research.